Back to results
US 11,693,013 B2Granted
Method relating to myostatin pathway inhibition
AssigneeUCL Business PLC
InventorsThomas Voit, Julie Dumonceaux, Virginie Mariot
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUCL Business PLC
InventorsThomas Voit, Julie Dumonceaux, Virginie Mariot
Estimating the term…
The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.
A method for determining whether a subject having or suspected of having a muscle atrophy or a muscle wasting condition will respond to treatment with a myostatin pathway inhibitor, the method comprising:
A method for treating muscle atrophy or a muscle wasting condition, the method comprising:
A method for determining inclusion of a subject, having or suspected of having muscle atrophy or a muscle wasting condition into a clinical trial for evaluation of a myostatin pathway inhibitor, the method comprising:
A method for determining whether a subject having or suspected of having a muscle atrophy or a muscle wasting condition will respond to treatment with a myostatin pathway inhibitor, the method comprising:
A method for determining whether a subject having or suspected of having a muscle atrophy or a muscle wasting condition will respond to treatment with a myostatin pathway inhibitor, the method comprising:
A method for treating muscle atrophy or a muscle wasting condition, the method comprising:
A method for treating muscle atrophy or a muscle wasting condition, the method comprising:
A method for determining inclusion of a subject, having or suspected of having muscle atrophy or a muscle wasting condition into a clinical trial for evaluation of a myostatin pathway inhibitor, the method comprising:
A method for determining inclusion of a subject, having or suspected of having muscle atrophy or a muscle wasting condition into a clinical trial for evaluation of a myostatin pathway inhibitor, the method comprising:
Dependencies are inferred from the claim text.